CYTK•benzinga•May 1, 2025 at 08:47 PM

Cytokinetics Announces The U.S. FDA Has Extended The Prescription Drug User Fee Act Action Date For The New Drug Application For Aficamten For The Treatment Of Patients With Obstructive Hypertrophic Cardiomyopathy To December 26, 2025

No summary available.

Read the full article from the original source for complete details and context.

Article published on May 1, 2025 by benzinga